✦ LIBER ✦

EGFR activity in Her-2 overexpressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR

✍ Scribed by D. Gschwantler-Kaulich; Hudelist; W.J. Koestler; K. Czerwenka; R. Mueller; E. Ruecklinger; E. Kubista; C.F. Singer

Book ID: 118624590
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 135 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)80310-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine and Trastuzumab Combinations

Gemcitabine and Trastuzumab Combinations for Patients with Metastatic Breast Cancer Overexpressing HER2/neu

✍ Steven Stein; Angie DeMichele; Susan Domchek; Kevin Fox 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 112 KB

Her-2/neu and EGFR tyrosine kinase activ

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

The tumor suppression activity of E1A in

The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer

✍ Chang, Joe Yujiao; Xia, Weiya; Shao, Ruping; Sorgi, Frank; Hortobagyi, Gabriel N 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 657 KB

Phosphorylated HER-2 tyrosine kinase and

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)

✍ Rosa Giuliani; Virginie Durbecq; Angelo Di Leo; Marianne Paesmans; Denis Larsimo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 636 KB

444 Predictive outcome assessment and mo

444 Predictive outcome assessment and monitoring by serum testing for HER-2/neu, EGFR, uPA and CA 27.29 in metastatic breast cancer

✍ D. Lüftner; P. Henschke; R. Geppert; W. Carney; K.D. Wernecke; K. Possinger 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 171 KB

Clinical implications of HER-2/neu overe

Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer

✍ Menha Swellam; Lobna R. Ezz El Arab; Hussein A. Bushnak 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB